A recent study sought to examine the course of these patients after the age of 40, and to identify possible risk factors for a worse prognosis.
There has been an increase in life expectancy for individuals with congenital heart disease (CHD), including both simple defects as well as more complex ones, with the median age now at 40 years.
While patients with both CHD and pulmonary arterial hypertension (PAH) continue to have the worst morbidity and mortality, this group, too, is living longer than before. A recent study sought to examine the course of these patients after the age of 40, and to identify possible risk factors for a worse prognosis.
Data regarding these older patients are limited, said the authors, writing in the Journal of Clinical Medicine.
The retrospective, single-center study in Germany included all patients with a diagnosis of PAH-CHD under follow-up at a cardiology center who were 40 years of age or older at any point between January 2005 and December 2018. The primary endpoint was all-cause mortality.
The diagnosis was established and confirmed by echocardiography, cardiac MRI, and/or cardiac catheterization.
Underlying CHD was classified as follows:
Left and right ventricular systolic function was graded semi-quantitatively as normal, or mildly, moderately or severely impaired. Arrhythmias included any type of supraventricular or ventricular arrhythmia requiring treatment.
The study included 65 patients (67.7% female, mean age 45.19 [6.75] years); of these, 46 (70.8%) had a shunt lesion; 12 (18.5%) had PAH associated with complex congenital heart defects; 7 (10.8%) had segmental pulmonary hypertension due to major aorto-pulmonary collaterals. Down syndrome was present in 13 patients (20.0%).
During a median follow-up of 4.2 years (interquartile range [IQR] 1.2-7.5), 16 patients (24.6%) died; 3 were from cardiac causes; 1 from respiratory failure; 1 from a cerebrovascular accident; and 11 from unknown causes.
About one-third of the patients required unplanned/emergency hospital admissions.
On univariate analysis, NT-proBNP (log), creatinine, and a previous history of ventricular arrhythmias were predictors of all-cause mortality.
Upon multivariate analysis, only NT-proBNP (log) (HR, 4.1; 95% CI, 1.2-14.4, P = .029) and creatinine (HR, 16.3; 95% CI, 2.2-118.7; P = .006) remained as independent predictors of all-cause mortality.
The study had several limitations, including a small sample size, the retrospective nature of the work, and some missing variables, such as cause of death for 11 patients and results from the 6-minute walk test.
"Close surveillance, including regular blood analysis, is necessary to identify patients at risk," the authors concluded.
Reference
Maurer SJ, Stöckemann K, Pujol C, Hörer J, Ewert P, Tutarel O. Pulmonary arterial hypertension associated with congenital heart disease in adults over the age of 40 years. J. Clin. Med. 2020; 9(12), 4071. doi:10.3390/jcm9124071
Echocardiographic Assessment Shows Promise as Risk Predictor in PAH
August 29th 2025Close to 40% of patients with right heart failure and pulmonary arterial hypertension (PAH) who remain critically ill and require admittance to the intensive care unit die within 1 year of that hospitalization.
Read More
Tricuspid Regurgitation Reliable Prognostic Indicator of PAH Severity
August 13th 2025Despite knowledge of the benefits of right heart hemodynamic measures for evaluating patient prognosis in the setting of pulmonary arterial hypertension (PAH), gaps remain in a defined role for tricuspid regurgitation as it relates to echocardiographic phenotype.
Read More
Lung Transplant Referrals Lag for High-Risk Patients With PAH
July 18th 2025Despite recommendations on early referral for lung transplantation in cases of pulmonary arterial hypertension (PAH), there is a lack of in-depth understanding of this current landscape; in this analysis, clinical parameter data were used to compare outcomes between patients who were and were not referred for lung transplantation.
Read More